Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
| Autor: | John R. White, Yan Kiriakov, Debbie Hinnen, Melissa Magwire, Neil Skolnik |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Agonist
Liraglutide Insulin glargine medicine.drug_class business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Pharmacology Hypoglycemia medicine.disease Feature Articles 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine chemistry Diabetes mellitus Internal Medicine medicine business medicine.drug |
| Zdroj: | Clinical Diabetes : A Publication of the American Diabetes Association |
| ISSN: | 1945-4953 0891-8929 |
| DOI: | 10.2337/cd17-0048 |
| Popis: | IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/lixisenatide—have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|